Serum asymmetric dimethylarginine level correlates with the progression and prognosis of amyotrophic lateral sclerosis
-
- Kensuke Ikenaka
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
-
- Yasuhiro Maeda
- Center for Joint Research Facilities Support Fujita Health University Toyoake Japan
-
- Yuji Hotta
- Department of Hospital Pharmacy Nagoya City University Graduate School of Pharmaceutical Sciences Nagoya Japan
-
- Seiichi Nagano
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
-
- Shinichiro Yamada
- Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
-
- Daisuke Ito
- Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
-
- Ryota Torii
- Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
-
- Keita Kakuda
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
-
- Harutsugu Tatebe
- T & T Brothers Corporation Chiba Japan
-
- Naoki Atsuta
- Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
-
- Cesar Aguirre
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
-
- Yasuyoshi Kimura
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
-
- Kousuke Baba
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
-
- Takahiko Tokuda
- T & T Brothers Corporation Chiba Japan
-
- Masahisa Katsuno
- Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
-
- Kazunori Kimura
- Department of Hospital Pharmacy Nagoya City University Graduate School of Pharmaceutical Sciences Nagoya Japan
-
- Gen Sobue
- Research Division of Dementia and Neurodegenerative Disease Nagoya University Graduate School of Medicine Nagoya Japan
-
- Hideki Mochizuki
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
抄録
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and purpose:</jats:title></jats:sec><jats:sec><jats:label /><jats:p>The aim was to investigate the association between serum asymmetric dimethylarginine (ADMA) levels and the progression and prognosis of amyotrophic lateral sclerosis (ALS), and to compare cerebrospinal fluid (CSF) and serum ADMA levels with other biomarkers of ALS.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Serum ADMA levels of sporadic ALS patients (<jats:italic>n</jats:italic> = 68), disease control patients (<jats:italic>n</jats:italic> = 54) and healthy controls (<jats:italic>n</jats:italic> = 20) were measured using liquid chromatography tandem mass spectrometry. Correlations of the ADMA level and other markers (nitric oxide and neurofilament light chain levels) were analyzed. Changes in the ALS Functional Rating Scale Revised (ALSFRS‐R) score from the onset of disease (ALSFRS‐R pre‐slope) was used to assess disease progression. Survival was evaluated using the Cox proportional hazards model and Kaplan–Meier analysis.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The serum ADMA level was substantially higher in patients with ALS than in healthy controls and disease controls. Serum ADMA level correlated with CSF ADMA level (<jats:italic>r</jats:italic> = 0.591, <jats:italic>p</jats:italic> < 0.0001) and was independently associated with the ALSFRS‐R pre‐slope (<jats:italic>r</jats:italic> = 0.505, <jats:italic>p</jats:italic> < 0.0001). Patients with higher serum ADMA levels had less favorable prognoses. CSF ADMA level significantly correlated with CSF neurofilament light chain level (<jats:italic>r</jats:italic> = 0.456, <jats:italic>p</jats:italic> = 0.0002) but not with nitric oxide level (<jats:italic>r</jats:italic> = 0.194, <jats:italic>p</jats:italic> = 0.219).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Serum ADMA level is an independent biomarker of ALS disease progression and prognosis and reflects the degree of motor neuron degeneration.</jats:p></jats:sec>
収録刊行物
-
- European Journal of Neurology
-
European Journal of Neurology 29 (5), 1410-1416, 2022-02-06
Wiley
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360861705598147456
-
- ISSN
- 14681331
- 13515101
-
- データソース種別
-
- Crossref
- KAKEN